CHCWM – Cancer & Hematology Centers of West Michigan

AstraZeneca SERENA-6

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor (SERENA-6)

Principal Investigator: Dr. Amy VanderWoude

For more information on this trial, read its profile on clinicaltrials.gov here.